Rigorous evaluation through clinical testing is vital for advancing safe and effective therapies. Clinical trials in regenerative medicine assess how engineered tissues, cell therapies, and gene editing approaches perform in human subjects across a spectrum of conditions. These trials must balance innovation with patient safety, following tightly regulated frameworks to validate therapeutic efficacy and monitor adverse outcomes. From early-phase feasibility studies to large-scale randomized trials, each stage is shaped by complex logistics, including manufacturing standards, delivery methods, and biomarker development. Clinical trials in regenerative medicine also face unique challenges like variability in cell behavior, individualized responses, and long-term monitoring. Despite these hurdles, progress continues steadily, establishing confidence in regenerative approaches through evidence-based evaluation.